eBay stock (EBAY) slips in premarket after 4% jump as jobs data, earnings loom
6 January 2026
1 min read

eBay stock (EBAY) slips in premarket after 4% jump as jobs data, earnings loom

New York, Jan 6, 2026, 08:15 EST — Premarket

  • EBAY down 0.3% premarket after a 3.9% rise in Monday’s regular session
  • Stock sits about 11% below its 52-week high after reclaiming the $90 handle
  • Investors watch U.S. payrolls on Jan. 9 and eBay’s expected earnings around Feb. 25

eBay shares slipped 0.3% to $90.18 in premarket trading on Tuesday, cooling after a 3.9% gain in Monday’s regular session. The stock traded between $86.64 and $91.41 on Monday and is about 11% below its 52-week high of $101.15; market calendars peg its next results around Feb. 25. 1

The pause matters because eBay is heading into a week of market-moving U.S. data with its own holiday-quarter report on deck later this month. Traders often treat round-number levels like $90 as a quick read on sentiment, and the stock just pushed back above it after a sharp one-day jump.

U.S. stock index futures were little changed early Tuesday after Wall Street rallied on Monday, lifting the Dow to a record high as energy and financial stocks climbed. “The broader equity markets are able to set aside what might have been fears of a prolonged engagement,” said Rob Haworth, senior investment strategist at U.S. Bank Wealth Management, after Washington’s move in Venezuela spurred risk-taking. 2

For eBay, the next debate is whether the holiday quarter shows steady demand and stable trading activity on its marketplace. Investors focus on gross merchandise volume, or GMV — the total value of goods sold on the platform — because it helps explain the pace of transactions beyond revenue alone.

In October, eBay forecast holiday-quarter adjusted profit of $1.31 to $1.36 per share and pointed to tariff and customs-related uncertainty that it said has weighed on small businesses and consumer confidence. CFO Peggy Alford told analysts the company saw “a deceleration in year-over-year volume growth” after the removal of the “de minimis” exemption — a rule that had allowed many packages valued at $800 or less to enter the U.S. duty-free. 3

Before that, the market’s next hard catalyst is the U.S. Employment Situation report for December, due at 8:30 a.m. ET on Friday, Jan. 9, according to the Labor Department’s schedule. 4

But the setup cuts both ways. If payrolls run hot and investors dial back expectations for Federal Reserve rate cuts, consumer and internet stocks can lose support fast, and any disappointment in eBay’s February update could widen the pullback.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Microchip Technology stock jumps about 4% premarket after sales forecast boost
Previous Story

Microchip Technology stock jumps about 4% premarket after sales forecast boost

Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next
Next Story

Cyclerion Therapeutics stock jumps in premarket after Medsteer deal — what CYCN investors watch next

Go toTop